|Articles|January 27, 2017
Aurinia Selects Worldwide for Phase III Lupus Trial
Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study.
Advertisement
Aurinia Pharma has announced the selection of Worldwide Clinical Trials as its CRO for the AURORA study, a Phase III clinical trial for the treatment of active lupus nephritis.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
2
FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results
3
Using AI and Tokenized Data to Match Patients to Protocols
4
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
